Fig. 1: 3-year EFS and 3-year OS among all patients. | Nature Communications

Fig. 1: 3-year EFS and 3-year OS among all patients.

From: Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors

Fig. 1

A – 3-year event-free survival (EFS) rate among all patients. Kaplan–Meier for EFS for the full study cohort (n =  35). The 3‑year EFS rate was 80 % (95 % CI, 66–93). Tick marks denote censored observations, and the shaded band represents the 95% CI. B 3-year overall survival (OS) rate among all patients. Kaplan–Meier curve for OS for the full study cohort (n =  35). The 3-year OS rate was 94% (95% CI, 86–100). Tick marks denote censored observations, and the shaded band represents the 95% CI.

Back to article page